{
  "folder": "IC-330",
  "content": "{{knowledge objective\n|Identifiant=OIC-330-06-A\n|Item_parent=Prescription and monitoring of the most common classes of medicines in adults and children, excluding anti-infectives (see item 177). Knowing the correct use of the main therapeutic classes.\n|Item_parent_short=Prescribing and monitoring the most common classes of medicines for adults and children, excluding anti-infectives (see item 177). Knowing the correct use of the main therapeutic classes.\n|Rank=A\n|Title=Anti-platelet agents: mechanisms of action, indications, side-effects, drug interactions, monitoring procedures and main causes of failure.\n|Description=Knowing the mechanisms of action\n|Rubric=Management\n|Contributors=\n|Order=6}}\n\n==Mechanisms of action==\n{| class=\"wikitable\"\n|'''Molecule'''\n|'''Mechanism of action''''\n|'''Reversibility'''\n|'''Duration of action'''\n|-\n|Acetylsalicylic acid (ASA)\n|Inhibition of platelet activation by inhibiting the synthesis of thromboxane A2\n|Irreversible\n|> 5 days\n|-\n|Thienopyridines\n\nClopidogrel\n\nPrasugrel\n|Inhibition of the ADP-dependent platelet activation pathway (P2Y12 receptor antagonist)\n|Irreversible\n|> 5 days\n|-\n|Tricagrelor\n|Inhibition of ADP pathway (P2Y12 receptor antagonist)\n|Reversible\n|4 days\n|}\n\n==Directions==\n{| class=\"wikitable\"\n|'''Molecule'''\n|'''Indications'''\n|'''Contraindications'''\n|-\n|ASA\n|Acute coronary syndrome (ACS) (in combination)\n\nPost-SCA (monotherapy)\n\nSecondary prevention of atherothrombotic ischaemic stroke\n\nObliterative arterial disease of the lower limbs (AOMI)\n|Active peptic ulcer disease\n|-\n|Clopidogrel\n|Acute phase SCA, in combination\n\nSecondary prevention of atherothrombotic ischaemic stroke\n\nAOMI\n|Severe hepatic impairment\n|-\n|Prasugrel\n|Acute phase SAA, in combination with ASA\n|Previous stroke or transient ischemic attack, severe hepatic impairment\n|-\n|Tricagrelor\n|Acute phase SA combined with abciximab\n<br />\n|History of intracranial haemorrhage, moderate to severe hepatic impairment.\n|}\n\n==Secondary effects==\n{| class=\"wikitable\"\n|'''Molecules'''\n|'''Undesirable effects'''\n|-\n|All\n|Risk of bleeding\n|-\n|ASA\n|Gastroduodenal ulcers, hypersensitivity reactions including asthma, hearing impairment.\n|-\n|Clopidogrel\n|Cytopenia, thrombotic thrombocytopenic purpura, dyspepsia, dysgeusia, confusion.\n|-\n|Prasugrel\n|Thrombotic thrombocytopenic purpura\n|-\n|Tricagrelor\n|dyspnea, bradycardia, increased creatinine, confusion, hyperuricemia, paresthesia\n|}\n\n==Drug interactions==\n{| class=\"wikitable\"\n|'''Molecules'''\n|'''Pharmacodynamic interactions'''\n|'''Pharmacokinetic interactions'''\n|-\n|Aspirin\n|Other antiaggregants\n\nHeparins\n\nFibrinolytics\n\nDirect oral anticoagulants\n\nVKA\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n|Not significant\n|-\n|Clopidogrel\n|Other antiaggregants\n\nHeparins\n\nFibrinolytics\n\nDirect oral anticoagulants\n\nVKA\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n|''CYP450 (CYP2C19) inhibitors'''\n\nfluconazole, protease inhibitors, esomeprazole, omeprazole)\n|-\n|Prasugrel\n|Other antiaggregants\n\nHeparins\n\nFibrinolytics\n\nDirect oral anticoagulants\n\nVKA\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n|Not significant\n|-\n|Ticagrelor\n|Other antiaggregants\n\nHeparins\n\nFibrinolytics\n\nDirect oral anticoagulants\n\nVKA\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n|CYP450 and P-glycoprotein inhibitors\n\nAzoles, protease inhibitors, erythromycin, clarithromycin, amiodarone, quinidine, naproxen\n\n\nCYP450 and P-glycoprotein inducers\n\nRifampicin, anticomitic drugs (phenytoin, phenobarbital, carbamazepine), St. John's wort\n<br />\n|}\n\n==Monitoring methods==\nClinical monitoring\n\n- Compliance\n\n- Tolerance: sign of bleeding\n\n- Efficacy: no recurrence of cardiovascular or cerebrovascular events due to atherothrombotic mechanisms\n\n'''Biological monitoring'''\n\nNo specific monitoring to detect toxicity, possible blood crase control (platelets)\n\n== Main causes of failure ==\n\n\nIntrinsic properties of the compound (partial reduction in the risk of recurrence)\n\nNon-compliance\n\nInsufficient control of other cardiovascular risk factors\n\nOther causes of vascular occlusive disease (embolism, dissection, etc.)",
  "question": {
    "question": "What is the mechanism of action of Thienopyridines (Clopidogrel, Prasugrel) in anti-platelet therapy?",
    "option_a": "Inhibition of thromboxane A2 synthesis",
    "option_b": "Inhibition of the ADP-dependent platelet activation pathway (P2Y12 receptor antagonist)",
    "option_c": "Inhibition of the COX-1 enzyme",
    "option_d": "Inhibition of the P2Y1 receptor",
    "correct_option": "B"
  }
}